Thirty-Six-Week Real-World Effectiveness of Lebrikizumab for Different Anatomical Sites and Clinical Signs in Atopic Dermatitis: Results from a Prospective Japanese Study.

Background

Anti-interleukin-13 antibody lebrikizumab is highly effective and tolerable for atopic dermatitis (AD). However, real-world data are limited on its effectiveness for different anatomical sites and clinical signs.

Objective

To evaluate the effectiveness of lebrikizumab on different anatomical sites and clinical signs of AD.

Methods

This study included 162 patients with moderate-to-severe AD who received lebrikizumab for 36 weeks. Eczema Area and Severity Index (EASI) was assessed at weeks 0, 4, 12, 24, and 36 on four anatomical sites (head/neck, trunk, upper limbs, and lower limbs) and four clinical signs (erythema, edema/papulation, excoriation, and lichenification).

Results

Lebrikizumab consistently decreased EASI on all anatomical sites and all clinical signs through 36 weeks. Week 36 achievement rates of EASI 100 on the trunk and upper limbs (46.3% and 48.8%) were higher compared to head/neck and lower limbs (28.9% and 33.3%), respectively. The percentage reduction of EASI and achievement rates of EASI 75 and EASI 100 at each time-point were highest for excoriation among clinical signs; week 36 achievement rates of EASI 100 for erythema, edema/papulation, excoriation, and lichenification were 35.3%, 38.2%, 60.6%, and 37.1%, respectively.

Conclusions

Lebrikizumab consistently improves eruptions across all anatomical sites and clinical signs in AD throughout 36 weeks.